Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody

Authors

Yongjun Yin, Washington University School of Medicine in St. Louis
Xiaodi Ren, Eli Lilly and Company
Craig Smith, Washington University School of Medicine in St. Louis
Qianxu Guo, Eli Lilly and Company
Maria Malabunga, Eli Lilly and Company
Ilhem Guernah, Eli Lilly and Company
Yiwei Zhang, Eli Lilly and Company
Juqun Shen, Eli Lilly and Company
Haijun Sun, Eli Lilly and Company
Nabil Chehab, Eli Lilly and Company
Nick Zoizos, Eli Lilly and Company
Dale L. Ludwig, Eli Lilly and Company
David M. Ornitz, Washington University School of Medicine in St. Louis

Journal

Disease Models & Mechanisms

Publication Date

2016

Volume

9

Issue

5

Inclusive Pages

563-71

Document Type

Open Access Publication

DOI

10.1242/dmm.024760

Rights and Permissions

Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody. Yongjun Yin, Xiaodi Ren, Craig Smith, Qianxu Guo, Maria Malabunga, Ilhem Guernah, Yiwei Zhang, Juqun Shen, Haijun Sun, Nabil Chehab, Nick Loizos, Dale L. Ludwig, David M. Ornitz. Disease Models and Mechanisms. (2016) 9: 563-571; doi: 10.1242/dmm.024760

Recommended Citation

Yin, Yongjun; Ren, Xiaodi; Smith, Craig; Guo, Qianxu; Malabunga, Maria; Guernah, Ilhem; Zhang, Yiwei; Shen, Juqun; Sun, Haijun; Chehab, Nabil; Zoizos, Nick; Ludwig, Dale L.; and Ornitz, David M., "Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody." Disease Models & Mechanisms. 9, 5. 563-71. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/4906